Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy

Research on immune checkpoint blockade therapy has made great progress in cancer immunotherapy, but the number of patients who benefit from this therapy remains limited. In this study, we examined the effects of monotherapy with systemic low-dose resiquimod, a synthesized TLR7 agonist, and examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishii, Naoto, Tachinami, Hidetake, Kondo, Yuta, Xia, Yulong, Kashima, Yoshihisa, Ohno, Tatsukuni, Nagai, Shigenori, Li, Lixin, Lau, Walter, Harada, Hiroyuki, Azuma, Miyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862579/
https://www.ncbi.nlm.nih.gov/pubmed/29568358
http://dx.doi.org/10.18632/oncotarget.24327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862579/
https://www.ncbi.nlm.nih.gov/pubmed/29568358
http://dx.doi.org/10.18632/oncotarget.24327

Ejemplares similares